Early Treatment with Pegylated Interferon Lambda for Covid-19.
Gilmar ReisEduardo A S Moreira SilvaDaniela C Medeiros SilvaLehana ThabaneVitoria H S CamposThiago S FerreiraCastilho V Q SantosAna M R NogueiraAna P F G AlmeidaLeonardo C M SavassiAdhemar D Figueiredo-NetoAna C F DiasAdelino M Freire JúniorCarina BitarãesAline C MilagresEduardo D CallegariMaria I C SimplicioLuciene B RibeiroRosemary OliveiraOfir HarariLindsay A WilsonJamie I ForrestHinda RutonSheila SpraguePaula McKayChristina M GuoEve H Limbrick-OldfieldSteve KantersGordon H GuyattCraig R RaynerChristopher KandelMia J BiondiRobert KozakBettina HansenM Atif ZahoorPaul AroraColin HislopIngrid ChoongJordan J FeldEdward J MillsJeffrey S Glennnull nullPublished in: The New England journal of medicine (2023)
Among predominantly vaccinated outpatients with Covid-19, the incidence of hospitalization or an emergency department visit (observation for >6 hours) was significantly lower among those who received a single dose of pegylated interferon lambda than among those who received placebo. (Funded by FastGrants and others; TOGETHER ClinicalTrials.gov number, NCT04727424.).